The ascendancy of Viagra and its influence on the pharmaceutical landscape presents a intricate question for investors. While the first sales data were astounding, the patent has lapsed, leading to a wave of generic alternatives that are chipping away at revenue. Furthermore, the sector is facing challenges related to aging trends and changing h… Read More